132
Participants
Start Date
December 19, 2023
Primary Completion Date
November 2, 2035
Study Completion Date
November 2, 2035
Linvoseltamab
Linvoseltamab will be administered by intravenous (IV) infusion
RECRUITING
Perlmutter Cancer Center, New York
RECRUITING
Columbia University _ New York Presbyterian, New York
RECRUITING
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
RECRUITING
Stony Brook University Hospital, Stony Brook
RECRUITING
Universitary Hospital La Princesa, Madrid
RECRUITING
Clinica Universidad de Navarra - Madrid, Madrid
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
Hospital Universitario Quiron Salud Madrid, Pozuelo de Alarcón
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Hospital Universitario Central De Asturias, Oviedo
RECRUITING
Hospital Universitario de Salamanca, Salamanca
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
La Fe University Hospital, Valencia
RECRUITING
Karmanos Cancer Institute, Detroit
NOT_YET_RECRUITING
CHU De Lille, Lille
RECRUITING
Hopital Saint Louis, Paris
RECRUITING
Hopital Pitié Salpetriere APHP, Paris
RECRUITING
Hopital Necker, Paris
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Colorado Blood Cancer Institute/SCRI, Denver
RECRUITING
Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers
RECRUITING
University of California Los Angeles (UCLA), Los Angeles
RECRUITING
UC Irvine Health, Orange
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier
RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
RECRUITING
Hospital Germans Trias i Pujol, Badalona
RECRUITING
Hospital General Universitario Doctor Balmis Alicante, Alicante
RECRUITING
Hospital Clinic de Barcelona, Barcelona
RECRUITING
Institut Catala dOncologia (ICO Hospitalet), Barcelona
Regeneron Pharmaceuticals
INDUSTRY